Name: MM-102
Price: 209.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    MM-102 is an antagonist of MLL1 with IC50 value of 2.4nM [1].
    Mixed lineage leukemia 1 (MLL1) is a histone H3 lysine 4 (H3K4) methyltransferase. The interaction of MLL1 and WDR5 is essential for MLL1 enzymatic activity and is a target for the treatment of acute leukemia. MM-102 is a peptidomimetic of MLL1. It has a high binding affinity to WDR5 with IC50 value of 2.4nM [1].
    MM-102 is reported to reduce the expression of MLL1 targeted genes HoxA9 and Meis-1 in MLL1-AF9 transduced murine cells. Since these two genes are required for MLL1 mediated leukemogenesis, MM-102 is found to inhibit cell growth of leukemia cells harboring MLL1 fusion proteins. It dose-dependently inhibits the cell growth in the MV4;11 and KOPN8 cell lines with IC50 values both of 25μM[1].
    
    [1] Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2013 Jan 16;135(2):669-82.
- Properties
  - Alternative Name
    
    N-[bis(4-fluorophenyl)methyl]-1-[[(2S)-5-(diaminomethylideneamino)-2-[[2-ethyl-2-(2-methylpropanoylamino)butanoyl]amino]pentanoyl]amino]cyclopentane-1-carboxamide
    
    CAS Number
    
    1417329-24-8
    
    Molecular Formula
    
    C35H49F2N7O4
    
    Molecular Weight
    
    669.8
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥22.6 mg/mL in EtOH; ≥67 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Li N, Yang L, et al. "BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc." Cell Death Dis. 2018 Jul 9;9(7):761. PMID:29988031

MM-102

MM-102

Background

We Also Recommend

NVP-ADW742

SC-514

UNC1999